Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
mFOLFOX in gemcitabine-refractory biliary tract cancer
NCT01127555Phase 2Completed
- Sponsor
- Chung-Ang University
- Start
- Apr 2010
- Primary completion
- Jun 2012
- Modality
- DNA Intercalators/Alkylators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of oxaliplatin, folinic acid and fluorouracil in biliary tract cancer (BTC), sponsored by Chung-Ang University. Primary endpoint: Response Rate at 1 year. Started Apr 2010; status: completed.
02
Drugs
oxaliplatinfolinic acidfluorouracil
03
Conditions
biliary tract cancer (BTC)
Beyond the preview
Go deeper on NCT01127555.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01127555.